Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Castle Biosciences Inc (NQ: CSTL )

29.57 +2.04 (+7.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 721,727
Open 28.10
Bid (Size) 29.12 (1)
Ask (Size) 30.59 (1)
Prev. Close 27.53
Today's Range 28.10 - 30.45
52wk Range 12.07 - 30.45
Shares Outstanding 25,167,365
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q2 2024
CSTL stock results show that Castle Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
+34.65%
+34.65%
1 Month
+53.13%
+53.13%
3 Month
+20.55%
+20.55%
6 Month
+20.67%
+20.67%
1 Year
+58.72%
+58.72%

More News

Read More
Castle Biosciences Reports Second Quarter 2024 Results
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
From Castle Biosciences Inc.
Via Business Wire
ON Semiconductor Posts Upbeat Earnings, Joins Oil States International, CommScope Holding And Other Big Stocks Moving Higher On Monday
Via Benzinga
Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Honored with Top Workplaces Awards
From Castle Biosciences Inc.
Via Business Wire
Top 5 Health Care Stocks That May Explode In July
Via Benzinga
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
From Castle Biosciences Inc.
Via Business Wire
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”
From Castle Biosciences Inc.
Via Business Wire
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
From Castle Biosciences Inc.
Via Business Wire
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
From Castle Biosciences Inc.
Via Business Wire
CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Castle Biosciences Reports First Quarter 2024 Results
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
From Castle Biosciences Inc.
Via Business Wire
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
From Castle Biosciences Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.